rmc-035
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2021 (NCT04829916)
Timeline
Indications
Mechanism of action
- Protein AMBPSupplementation
AMBP supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06475274 | Phase 2 | Aug 27, 2024 | Guard Therapeutics AB |
| NCT05126303 | Phase 2 | Dec 31, 2021 | Guard Therapeutics AB, University of Munster |
| NCT04829916 | Phase 1 | Mar 16, 2021 | Guard Therapeutics AB |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guard Therapeutics AB | For profit | 3 | 3 | 2 | 2021 |
| University of Munster | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1